Tilray is a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. The company portfolio includes brand such as Sweet Water Brewing, Montauk Brewing, Brew Dog, Shock Top, 10 Barrell, Breckenridge Brewery, Blue Point Brewing, Breckenridge Distillery, Revolver, Terrapin, Broken Coast, Good Supply, Redecan, Solei, Tilray, ARX, XMG, Manitoba Harvest and Hi-Ball. The company has four segment Beverage, Cannabis, Distribution and Wellness. The majority of the revenue is generated from Distribution business which encompasses the purchase and resale of pharmaceuticals products to customers.
Last trade$2.35
Day change+$0.005 (+0.21%)
Day range$2.32 – $2.37
Volume2,905,281
Market cap$346M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$345.82M
Price / earnings
—
Price / book
0.21×
Price / sales
0.36×
EV / sales
0.35×
EV / EBITDA
-21.97×
Profitability
Earnings per share
-$1.11
Return on assets
-7.05%
Return on equity
-10.12%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.12×
Current ratio
1.88×
Quick ratio
1.11×
Cash ratio
0.5×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$84.34M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TLRY, quarterly periods
Line item
Q1 FY2027 Aug 31, 2026
Q4 FY2026 May 31, 2026
Q3 FY2026 Feb 28, 2026
Q2 FY2026 Nov 30, 2025
Q1 FY2026 Aug 31, 2025
Q4 FY2025 May 31, 2025
Q3 FY2025 Feb 28, 2025
Q2 FY2025 Nov 30, 2024
Revenue
$257.15M
$281.71M
$206.73M
$217.51M
$209.5M
$224.54M
$185.78M
$210.95M
Cost of revenue
$179.64M
$191.19M
$151.78M
$160.01M
$152.03M
$156.9M
$133.77M
$149.73M
Gross profit
$77.51M
$90.52M
$54.95M
$57.5M
$57.47M
$67.63M
$52.01M
$61.22M
Selling, general and administrative
$86.94M
$88.64M
$69.54M
$72.94M
$64.13M
$61.22M
$59.94M
$71.88M
Research and development
$89K
$180K
$62K
$78K
$41K
$34K
$85K
$60K
Total operating expenses
$101.56M
$106.98M
$81.34M
$79.78M
$55.38M
$1.51B
$811.94M
$103.44M
Operating income
-$24.05M
-$16.45M
-$26.39M
-$22.28M
$2.09M
-$1.44B
-$759.93M
-$42.22M
Interest expense
-$6.48M
-$23.66M
$0
$0
-$6.7M
-$29.95M
$0
$0
Income before taxes
-$38.31M
-$24.07M
-$23.26M
-$39.96M
-$772K
-$1.39B
-$792.33M
-$83.24M
Income taxes
$1.73M
$13.86M
$1.97M
$3.55M
-$2.29M
-$125.14M
$1.2M
$2.04M
Net income
-$40.03M
-$37.93M
-$25.23M
-$43.51M
$1.51M
-$1.27B
-$793.53M
-$85.28M
Net income attributable to common shareholders
-$43.14M
-$49.57M
-$26.57M
-$44.93M
-$322K
-$1.27B
-$789.44M
-$85.34M
EBITDA
-$2.18M
-$3.52M
-$4.94M
-$4.49M
$19.53M
$16.13M
-$18.26M
-$398K
Basic earnings per share
-$0.32
-$0.42
-$0.24
-$0.41
$0.00
-$13.95
-$8.69
-$0.99
Diluted earnings per share
-$0.32
-$0.42
-$0.24
-$0.41
$0.00
-$13.95
-$8.69
-$0.99
Recent news
Company coverage with links to the original publishers.
Tilray Brands has not made a bid for Aurora Cannabis despite being an acquisition-hungry company, as its strategic focus has shifted toward U.S. beverage acquisitions and craft brewing rather than expanding in the competitive Canadian cannabis market. The company recently announced consolidation efforts in Canada to focus on profitability, making a major acquisition of a Canadian producer like Aurora less attractive to its long-term strategy.
Tilray Brands' three Oregon craft beer subsidiaries—10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing—have been named Official Craft Beer Partners of the Portland Trail Blazers. 10 Barrel also becomes the team's first Official Canned Cocktail Partner. The partnership expands craft beverage offerings at Moda Center through new venues like Schonely's Oregon Beer Hall and extends to the Rip City Bar Network.
Green Thumb Industries (GTBIF) reported Q3 2026 sales growth of 11.3% to $324.4 million but missed earnings estimates with a 2-cent loss per share. While retail and CPG revenues grew 10% and 16% respectively, the company faces ongoing pricing pressure and increased competition. Management expects flat to slightly lower Q4 revenues and continued price compression, though the company maintains financial strength with $316 million in cash and continues shareholder buybacks. Analysts recommend a wait-and-watch approach given industry headwinds.
The U.S. government's reclassification of medical cannabis from Schedule I to Schedule III primarily benefits U.S.-based cannabis operators through lower tax bills, not Canadian producer Tilray. While rescheduling may be a step toward legalization, it doesn't guarantee future reform and could take years to materialize. Investors should be cautious about overreacting to rescheduling news, as Tilray's stock has historically surged temporarily on cannabis reform announcements only to decline to new lows.
Tilray announced a consolidation of its Canadian operations expected to generate $10 million in annual cost savings, leading to slightly raised adjusted EBITDA guidance for fiscal 2027 ($70-75 million vs. previous $68-75 million). However, the company continues to burn cash and faces challenges in the competitive Canadian cannabis market with low margins. Analysts remain cautious, suggesting investors take a wait-and-see approach as the improvements are insufficient to make the stock a compelling buy.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.